Search | Clinical Trials Finder

The live registry is temporarily unavailable. These stored records may be incomplete or out of date. Check the official record for current status and contact information.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 4:33 PM EDT

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 865–888 of 3,258 matching trials from the local directory fallback.

Filters: Not yet recruiting Clear all

Conditions: Inpatient Experience Survey Administration, Inpatient Experience Survey Response, Inpatient Pediatric Care, Inpatient Pediatric Engagement and Shared Decision-Making
Interventions: Anonymous Safety Reporting with Impact Website, Identified Safety Reporting, Safety Reporting Integration Toolkit, Text Plus In-Person Enrollment Strategy, Text-Only Enrollment Strategy; Behavioral · Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 13 Years and older
Enrollment: 21,800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 8
States / cities: Los Angeles, California • Oakland, California • Sacramento, California + 5 more

Conditions: Clear Cell Renal Cell Cancer (ccRCC), Renal Cell Cancer Metastatic, Renal Cell Cancer, Recurrent, Renal Cell Carcinoma (Kidney Cancer), Renal Cell Carcinoma (RCC), ccRCC
Interventions: 177Lu-TLX250; Drug
Lead sponsor: Telix Pharmaceuticals (Innovations) Pty Limited; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 8
States / cities: Duarte, California • San Diego, California • Miami, Florida + 5 more

Conditions: Adenotonsillectomy, Postoperative Pain
Interventions: Acetaminophen, Celecoxib, Dexamethasone; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 2 Years to 18 Years
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: New York, New York

Conditions: Hypertension
Interventions: Self-Titration; Other
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 35 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2028
U.S. locations: 1
States / cities: Somerville, Massachusetts

Conditions: Behavioral Intervention, Fitness Tracker, Physical Activity, Primary Care
Interventions: Physical Activity Counseling Tool (PACT); Behavioral
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 80 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2028
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Anxiety, Depression, Drug Use, Family Relationships, LGBTQ, Minority Stress, Racial Disparities, Sexual Risk Reduction, Teen Dating Violence
Interventions: Adapted Lakota Family Acceptance Program; Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 13 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: Pine Ridge, South Dakota • Rapid City, South Dakota

Conditions: HIV Infections
Interventions: SEPA+PrEP Women; Behavioral
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older · Female only
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Coral Gables, Florida

Conditions: Diabetes, Diabetic Retinopathy, Proliferative Diabetic Retinopathy
Interventions: PDS Implant filled with 100 mg/mL Ranibizumab, Ranibizumab; Device · Drug
Lead sponsor: Southeast Retina Center, Georgia; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Augusta, Georgia

Conditions: Systemic Sclerosis, Systemic Sclerosis (SSc), Systemic Sclerosis (Scleroderma), Systemic Sclerosis - 2013 ACR/EULAR Classification Criteria, Systemic Sclerosis Pulmonary, Systemic Sclerosis With Lung Involvement
Interventions: C-CAR168; Biological
Lead sponsor: AbelZeta Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2030
U.S. locations: 1
States / cities: Gilbert, Arizona

Conditions: Consciousness, Level Altered
Interventions: Functional Magnetic Resonance Imaging (fMRI), Low-intensity focused ultrasound pulsation (LIFUP), Magnetic Resonance Spectroscopy, Multi-modal glymphatic function MRI; Device
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years to 40 Years
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2032
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Disordered Eating Behaviors, Weight Management
Interventions: Not listed
Lead sponsor: University of California, San Francisco; Other
Eligibility: 12 Years to 21 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Autoimmune, MS, MS (Multiple Sclerosis), Multiple Sclerosis, Neuro-Degenerative Disease, Neuro-Degenerative Diseases, Primary Progressive Multiple Sclerosis, Primary Progressive Multiple Sclerosis (PPMS), Secondary Progress Multiple Sclerosis (SPMS)
Interventions: C-CAR168; Drug
Lead sponsor: AbelZeta Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2030
U.S. locations: 2
States / cities: Gilbert, Arizona • La Jolla, California

Conditions: Glaucoma, Open-angle, Primary Open Angle Glaucoma (POAG)
Interventions: Nicotinamide, Standard Glaucoma Therapy; Drug · Other
Lead sponsor: University of Chicago; Other
Eligibility: 40 Years to 80 Years
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2030
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Acute Myeloid Leukemia (AML)
Interventions: Active Default; Behavioral
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2027 – 2028
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Mucosal Immune Response to Influenza Vaccination
Interventions: FluMist (Live Attenuated Influenza Vaccine); Biological
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Aging, Biomarkers of Aging, Longevity
Interventions: Psilocybin (Usona Institute); Drug
Lead sponsor: Charles Raison; Other
Eligibility: 60 Years to 80 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Edwards, Colorado

Conditions: GERD
Interventions: Bravo pH monitoring sessions; Device
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years to 90 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Exercise Training, Fatigue, Systemic Lupus Erthematosus
Interventions: Personalized Home-Based High-Intensity Interval Training; Behavioral
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Hepatocellular Carcinoma (HCC), Liver Cancer, Adult
Interventions: Medical Record Review, Nitroglycerin, Parenchymal Blood Volume (PBV) Imaging; Other · Drug · Procedure
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 2
States / cities: San Francisco, California

Conditions: Rheumatic Heart Disease in Children
Interventions: CHW Delivered SAP Adherence Supports; Behavioral
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: Not listed
Enrollment: 308 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Dupuytren's Contracture
Interventions: Radiation Therapy; Radiation
Lead sponsor: Yale University; Other
Eligibility: 30 Years and older
Enrollment: 158 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Greenwich, Connecticut

Conditions: Locally Advanced Gastrointestinal Stromal Tumor, Metastatic Gastrointestinal Stromal Tumor, Recurrent Gastrointestinal Stromal Tumor, Refractory Malignant Gastrointestinal Stromal Tumor, Unresectable Malignant Gastrointestinal Stromal Tumor
Interventions: Aldesleukin, Biospecimen Collection, Chest Radiography, Computed Tomography, Cyclophosphamide, Echocardiography Test, Filgrastim, Fludarabine, Magnetic Resonance Imaging, Multigated Acquisition Scan, Positron Emission Tomography, Surgical Procedure, Tumor Infiltrating Lymphocyte Therapy; Biological · Procedure · Drug
Lead sponsor: Joal Beane; Other
Eligibility: 18 Years to 75 Years
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Urology
Interventions: Preoperative Outreach; Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Recurrent Nodal Marginal Zone Lymphoma, Recurrent Splenic Marginal Zone Lymphoma, Refractory Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Refractory Nodal Marginal Zone Lymphoma, Refractory Splenic Marginal Zone Lymphoma
Interventions: Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Mosunetuzumab, Polatuzumab Vedotin, Positron Emission Tomography, Survey Administration, Zanubrutinib; Procedure · Biological · Drug + 1 more
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2035
U.S. locations: 14
States / cities: Newark, Delaware • Coeur d'Alene, Idaho • Post Falls, Idaho + 10 more

Search by objective public record fields.

FIQS Dissemination and Implementation

Phase 2a Study to Assess Safety and Efficacy of Two 177Lu-TLX250 Dosing Regimens in Advanced Relapsed or Recurrent ccRCC

Preoperative Celecoxib and Acetaminophen Versus Acetaminophen Alone for Pain Control After Pediatric Adenotonsillectomy

Antihypertensive Self-titration in US Primary Care

Guided Physical Activity Counseling: A Pilot Study

Lakota Family Acceptance Project Pilot RCT

SEPA+PrEP-Women Pilot Trial for HIV Prevention Among Women at Risk for HIV

Continuous Delivery of Ranibizumab Via the Port Delivery System for Proliferative Diabetic Retinopathy-related Vitreous Hemorrhage With Pars Plana Vitrectomy and Limited PRP.

C-CAR168, an Autologous Anti-CD20/BCMA Chimeric Antigen Receptor T-Cell Therapy, in Participants With Systemic Sclerosis (SSc) Refractory to Standard Therapy

Investigating Near-Threshold Perception During Ultrasonic Deep Brain Stimulation

GLP-1 Impacts on Weight Management

C-CAR168, an Autologous Anti-CD20/BCMA Chimeric Antigen Receptor T-Cell Therapy, in Participants With Progressive Multiple Sclerosis Refractory to Standard Therapy

Nicotinamide for Retinal Protection in Primary Open-Angle Glaucoma (NADIR Trial)

Improving Delivery of Aging-Related Supportive Care for Older Adults With Acute Myeloid Leukemia

How Healthy Adults Respond to the Nasal Flu Vaccine

Psilocybin Effects on Healthy Aging Biomarkers and Purpose in Life

PROPER-GERD: A Prospective Crossover Study to Evaluate Probe Placement Optimization for Reflux Testing in Women and Lower-BMI Patients

Home-Based High-Intensity Interval Training in Systemic Lupus Erythematosus

Utilize Imaging to Assess Changes in Hepatocellular Carcinoma Perfusion as Potentiated by Intra-Arterial Nitroglycerin

Adapting Enhanced Supports to Improve Patient Adherence to Secondary Antibiotic Prophylaxis for Rheumatic Heart Disease

DEPART Study at Yale

Autologous Tumor Infiltrating Lymphocytes With Interleukin-2 for the Treatment of Locally Advanced, Recurrent or Metastatic Gastrointestinal Stromal Tumors

Preoperative Outreach to Improve Surgical Attendance

Testing Mosunetuzumab Alone, With Zanubrutinib, or With Polatuzumab Vedotin for Treating Marginal Zone Lymphoma That Came Back or Didn't Get Better With Treatment